Home › Research › Biomarkers
Biomarkører for Alzheimers sykdom – et fremskritt for hvem?
Peter Fusdahl, Miguel Germán Borda. Tidsskrift for Den norske legeforening, 2026-05-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
12.05.2026: Debatt - En enkel blodprøve kan nå påvise fosforylert tau-protein 217 (p-tau217) – et biologisk tegn på Alzheimers sykdom, som kan være til stede mange år før de første symptomene viser seg.
What this study adds
Evidence grade: Low
A simple blood test can now detect phosphorylated tau protein 217 (p-tau217), a biological sign of Alzheimer's disease that may be present many years before the first symptoms. This is a diagnostic development; the text does not report any treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fusdahl, P., & Borda, M. G. (2026). Biomarkører for Alzheimers sykdom – et fremskritt for hvem? Tidsskrift for Den norske legeforening. https://doi.org/10.4045/tidsskr.26.0240
Vancouver
Fusdahl P, Borda MG. Biomarkører for Alzheimers sykdom – et fremskritt for hvem? Tidsskrift for Den norske legeforening. 2026. doi:10.4045/tidsskr.26.0240. PMID: 42237823.
BibTeX
@article{fusdahl2026-42237823,
author = {Fusdahl, Peter and Borda, Miguel Germán},
title = {{Biomarkører for Alzheimers sykdom – et fremskritt for hvem?}},
journal = {Tidsskrift for Den norske legeforening},
year = {2026},
doi = {10.4045/tidsskr.26.0240},
pmid = {42237823},
url = {https://doi.org/10.4045/tidsskr.26.0240}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- 12.05.2026: Debatt - En enkel blodprøve kan nå påvise fosforylert tau-protein 217 (p-tau217) – et biologisk tegn på Alzheimers sykdom, som kan være til stede mange år før de første symptomene viser seg.
Why it matters
A simple blood test can now detect phosphorylated tau protein 217 (p-tau217), a biological sign of Alzheimer's disease that may be present many years before the first symptoms. This is a diagnostic development; the text does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 29 of the 97 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Tidsskrift for Den norske legeforening) |
| Journal's citation record | 0 / 4 | Tidsskrift for Den norske legeforening: journal h-index 37 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Miguel Germán Borda: h-index 22 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42237823) |
| Free to read | 2 / 2 | Free to read |
| Points | 29 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 97 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.4045/tidsskr.26.0240
- PubMed: 42237823
- Original source →
- Free full text: Tidsskrift for Den norske legeforening →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also in Biomarkers
137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.